184 related articles for article (PubMed ID: 9431010)
1. [Genetic polymorphism of drug metabolizing enzymes].
Yokoi T; Kamataki T
Seikagaku; 1997 Oct; 69(10):1196-9. PubMed ID: 9431010
[No Abstract] [Full Text] [Related]
2. [Genetic polymorphisms of drug metabolizing enzymes].
Fujieda M; Yamazaki H; Kamataki T
Gan To Kagaku Ryoho; 2002 May; 29(5):663-8. PubMed ID: 12040668
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics of cytochromes P450.
Hasler JA
Mol Aspects Med; 1999; 20(1-2):12-24, 25-137. PubMed ID: 10575648
[No Abstract] [Full Text] [Related]
4. Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese.
Yokoi T; Kamataki T
Pharm Res; 1998 Apr; 15(4):517-24. PubMed ID: 9587945
[TBL] [Abstract][Full Text] [Related]
5. Phenotyping of drug metabolism in infants and children: potentials and problems.
Rane A
Pediatrics; 1999 Sep; 104(3 Pt 2):640-3. PubMed ID: 10469807
[No Abstract] [Full Text] [Related]
6. [Individualization of drug therapy and pharmacogenetics].
Yamamoto I; Azuma J
Nihon Rinsho; 1998 Mar; 56(3):579-83. PubMed ID: 9549339
[TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population.
Bozina N; Granić P; Lalić Z; Tramisak I; Lovrić M; Stavljenić-Rukavina A
Croat Med J; 2003 Aug; 44(4):425-8. PubMed ID: 12950145
[TBL] [Abstract][Full Text] [Related]
8. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
Streetman DS; Bleakley JF; Kim JS; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577
[TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphism of cytochrome P450 and methods for its determination.
Buzková H; Pechandová K; Slanar O; Perlík F
Prague Med Rep; 2006; 107(4):383-93. PubMed ID: 17402551
[TBL] [Abstract][Full Text] [Related]
10. CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system.
Ford GA; Wood SM; Daly AK
Br J Clin Pharmacol; 2000 Jul; 50(1):77-80. PubMed ID: 10886124
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of inhibitory drug interactions during drug development: genetic polymorphisms must be considered.
Lee LS; Nafziger AN; Bertino JS
Clin Pharmacol Ther; 2005 Jul; 78(1):1-6. PubMed ID: 16003286
[No Abstract] [Full Text] [Related]
12. Genetic polymorphism of CYP2D6 and CYP2C19 in east- and southern African populations including psychiatric patients.
Dandara C; Masimirembwa CM; Magimba A; Sayi J; Kaaya S; Sommers DK; Snyman JR; Hasler JA
Eur J Clin Pharmacol; 2001 Apr; 57(1):11-7. PubMed ID: 11372584
[TBL] [Abstract][Full Text] [Related]
13. Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors.
Spigset O; Hedenmalm K; Dahl ML; Wiholm BE; Dahlqvist R
Acta Psychiatr Scand; 1997 Nov; 96(5):379-84. PubMed ID: 9395157
[TBL] [Abstract][Full Text] [Related]
14. Genotoxicology and risk assessment in the era of the human genome project.
Vorce RL; Stemmer PM
J Toxicol Clin Toxicol; 1996; 34(5):521-3. PubMed ID: 8800191
[No Abstract] [Full Text] [Related]
15. Antidepressants and drug-metabolizing enzymes--expert group report.
Meyer UA; Amrein R; Balant LP; Bertilsson L; Eichelbaum M; Guentert TW; Henauer S; Jackson P; Laux G; Mikkelsen H; Peck C; Pollock BG; Priest R; Sjöqvist F; Delini-Stula A
Acta Psychiatr Scand; 1996 Feb; 93(2):71-9. PubMed ID: 8686486
[TBL] [Abstract][Full Text] [Related]
16. Adverse drug reaction monitoring in Jena. Relevance of polymorphic drug metabolizing enzymes for inducing adverse drug reactions.
Hippius M; Buchardt C; Farker K; Kuhn UD; Reimann IR; Hoffmann A
Exp Toxicol Pathol; 2003 Jun; 54(5-6):417-21. PubMed ID: 12877354
[TBL] [Abstract][Full Text] [Related]
17. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages.
Kirchheiner J; Brøsen K; Dahl ML; Gram LF; Kasper S; Roots I; Sjöqvist F; Spina E; Brockmöller J
Acta Psychiatr Scand; 2001 Sep; 104(3):173-92. PubMed ID: 11531654
[TBL] [Abstract][Full Text] [Related]
18. [Genotyping of CYP2D6 and CYP2C19].
Slanar O; Drazd'áková M; Babiárová K; Pechandová K; Buzková H; Perlík F; Zima T
Cas Lek Cesk; 2007; 146(9):708-11. PubMed ID: 17966194
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics: role in modifying drug dosage regimens.
Mah JT; Wong JY; Lee EJ
Ann Acad Med Singap; 2000 Sep; 29(5):628-32. PubMed ID: 11126699
[TBL] [Abstract][Full Text] [Related]
20. [Status of pharmacogenomics and its future role in drug therapy].
Cascorbi I
Internist (Berl); 2002 Apr; 43(4):506-10. PubMed ID: 12053407
[No Abstract] [Full Text] [Related]
[Next] [New Search]